Diginex Unveils End-to-End Supply Chain Tool as Nasdaq Compliance and Resulticks Deal Loom

On June 4, Diginex introduced its Risk-to-Remedy solution, a comprehensive supply chain due diligence framework that merges the company’s LUMEN risk-assessment platform with APPRISE’s direct worker-engagement capabilities and the legal expertise of The Remedy Project. The product tackles a compliance market projected to swell from $3.8 billion in 2025 to $9.6 billion by 2034, driven by tightening regulations on responsible sourcing. Yet the market response has been anything but buoyant: shares closed the week at $1.00, shedding over 31% in five sessions, with the relative strength index plunging to 29.6 — well into oversold territory.

Parallel to the product rollout, Diginex updated investors on its planned acquisition of Resulticks Global Companies Pte. Limited. The long-stop date has been extended to June 12, 2026, after the deal missed previous deadlines of April 30 and May 29. The transaction would be transformative: Resulticks is expected to contribute roughly $150 million in annual revenue and between $46 million and $50 million in EBITDA. For context, Diginex itself generated just $3.6 million in revenue over the trailing twelve months and carries a market capitalization of approximately $34 million.

The stock remains under the shadow of potential delisting from the Nasdaq. In March 2026, the exchange formally warned Diginex after its closing price stayed below $1.00 for 30 consecutive trading days, violating Listing Rule 5550(a)(2). A 1-for-8 reverse stock split at the end of April mechanically lifted the share price, but the effect proved short-lived. This Friday, the stock closed at $1.04 — a weekly loss of 28% and a monthly decline of 33%, with the RSI at 30.4. Diginex has until September 21, 2026, to regain compliance.

Should investors sell immediately? Or is it worth buying Diginex?

Operationally, there are genuine bright spots. Diginex’s ESG data subsidiary, Matter, which serves institutions managing a combined $20 trillion in assets, boosted its automation rate for extracting carbon data from 25% to 80%. The new Risk-to-Remedy offering is part of a broader strategy to consolidate Plan A, Matter, The Remedy Project, and the core Diginex platform under a single technology umbrella.

The next critical date is June 12. If the Resulticks acquisition fails to close, Diginex loses the growth engine that currently underpins its valuation. Even if the deal goes through, the Nasdaq compliance clock continues to tick. With the share price hovering near $1.00 and annualized volatility running at 156%, the company must balance deal execution with restoring market confidence — all before two very different deadlines converge.

Ad

Diginex Stock: New Analysis - 6 June

Fresh Diginex information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Diginex analysis...

en | KYG286871044 | DIGINEX | boerse | 69491542 |